Amgen's new cancer drug treatment to cost US$178,000
Tue, Dec 23, 2014 - 5:50 AM
San Francisco
AMGEN Inc's leukaemia drug Blincyto will cost US$178,000 for a standard course of treatment, continuing a trend of high prices for immunotherapy, the newest wave of cancer treatments.
The price includes two US$89,000 cycles of therapy, the median duration of treatment...
Register to read this article. Log in if you are already a subscriber.Register to read this article. Log in if you are already a subscriber.Please log in or subscribe to continue reading.
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes